A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib - Regional Cancer Care Associates LLC

Clinical Trials

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung
Locations
Bethesda
Sponsor
Protocol Number
I4T-MC-JVCY
Cancer Diagnosis
To Learn More Call
201-510-0910